WO2024150261A1 - An oral pharmaceutical formulation and a method of preparation thereof - Google Patents

An oral pharmaceutical formulation and a method of preparation thereof Download PDF

Info

Publication number
WO2024150261A1
WO2024150261A1 PCT/JO2023/050001 JO2023050001W WO2024150261A1 WO 2024150261 A1 WO2024150261 A1 WO 2024150261A1 JO 2023050001 W JO2023050001 W JO 2023050001W WO 2024150261 A1 WO2024150261 A1 WO 2024150261A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
freeze
pharmaceutically active
active material
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JO2023/050001
Other languages
French (fr)
Inventor
Jehad NASEREDDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zarqa University
Original Assignee
Zarqa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zarqa University filed Critical Zarqa University
Priority to PCT/JO2023/050001 priority Critical patent/WO2024150261A1/en
Publication of WO2024150261A1 publication Critical patent/WO2024150261A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • the present disclosure relates to oral pharmaceutical formulations including carrier matrices for the oral delivery of a certain pharmaceutically active material, and more particularly to a pharmaceutical formulation that includes a polymeric carrier matrix of freeze-dried aerogel that rapidly disintegrates to release the pharmaceutically active material.
  • the oral delivery system of pharmaceuticals administration is preferred because of being well-established delivery system, patient friendly, and used for treating several diseases.
  • the oral delivery method suffers from challenges associated with poor oral bioavailability whether it is solubility, permeability, or stability-related. This could be overcome by the use of carrier matrices, self-emulsifying drug delivery systems, controlled release particles, tailor made nanoparticles, orally disintegrating tablets, or polymeric micelles.
  • the published article titled “Gelatin content governs hydration induced structural changes in silica-gelatin hybrid aerogels - Implications in drug delivery” discloses silica- gelatin hybrid aerogels with varying gelatin content (4-24 wt.%) which can be impregnated with active agents (e.g. ibuprofen) and used as drug delivery systems.
  • active agents e.g. ibuprofen
  • the active agents were amorphous, and homogeneously dispersed in the porous hybrid matrices as they were investigated by contrast variation neutron scattering experiments, those experiments showed the molecular level hybridization of the silica and the gelatin components of the aerogel carriers.
  • the gelatin content of the carrier can govern the kinetics of drug release so that both fast and retarded drug release can be accomplished with using silica-gelatin aerogels as carrier matrices.
  • the published article titled “Comparative Evaluation of HPMC, PVA and Gelatin as Matrices for Controlled Release Drug Delivery” discloses the use of gel-formers HPMC, PVA, and gelatin as polymeric matrices for formation of tablets, and compares the impact of each of the gel-formers on the drug release.
  • the average drug release of drug formulated from different types of polymers varied with the ratio of different polymers.
  • the PVA polymer showed best dissolution pattern between the polymers.
  • a pharmaceutical composition may include a freeze-dried aerogel configured to be a polymeric carrier matrix of a pharmaceutically active material, wherein the freeze-dried aerogel may include a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material intended to be orally delivered to a patient; an excipient configured to form and maintain a three-dimensional (“3D”) structure of the carrier matrix; and a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
  • a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material intended to be orally delivered to a patient
  • an excipient configured to form and maintain a three-dimensional (“3D”) structure of the carrier matrix
  • a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
  • the freeze-dried aerogel may further include a sweetener configured to sweeten the pharmaceutical composition.
  • the sweetener may be D - Mannitol.
  • the freeze-dried aerogel may further include a flavoring agent configured to facilitate an oral delivery of the pharmaceutically active material for pediatric patients.
  • the flavoring agent may be cherry syrup.
  • the plasticizer may be polyethylene glycol 400.
  • the excipient may be gelatin.
  • the solvent may be deionized water.
  • the pharmaceutically active material may be paracetamol.
  • the pharmaceutically active material may be acetylsalicylic acid.
  • compositions of the present disclosure further provide a method of preparing the oral pharmaceutical formulation, the method may comprise the steps of: Dissolving an excipient, and a plasticizer in a solvent to form a solution;
  • the method may further include dissolving a sweetener and a flavoring agent in the solution.
  • FIG.l illustrates a flow chart of a method of preparation of a pharmaceutical composition configured in accordance with embodiments of the present disclosure.
  • Embodiments of the present disclosure provide an oral pharmaceutical formulation that may act as an oral delivery system for drugs, the formulation may include a pharmaceutically active material; a freeze-dried aerogel configured to be a polymeric carrier matrix of the pharmaceutically active material, wherein the freeze-dried aerogel may include a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material; an excipient configured to form and maintain a 3D structure of the carrier matrix; and a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
  • the freeze-dried aerogel may further include a sweetener.
  • the sweetener may be D - Mannitol.
  • the freeze-dried aerogel may further include a flavoring agent configured to facilitate an oral delivery of the pharmaceutically active material for pediatric patients.
  • the flavoring agent may be cherry syrup.
  • the plasticizer may be polyethylene glycol 400.
  • the excipient may be gelatin.
  • the solvent may be deionized water.
  • the pharmaceutically active material may be paracetamol.
  • the pharmaceutically active material may be acetylsalicylic acid.
  • FIG. 1 illustrates a flowchart of a method for preparing the pharmaceutical formulation of the present disclosure.
  • the pharmaceutical formulation was synthesized and tested for different pharmaceutically active materials, such pharmaceutically active materials validated the use of the freeze- dried aerogel as a carrier matrix for an orally delivered active pharmaceutical material.
  • the pharmaceutically active materials were Paracetamol and Acetylsalicylic acid 400.
  • the method of preparing the pharmaceutical formulation may include the steps of: Dissolving an excipient, and a plasticizer in a solvent to form a solution (process block 1 - i);
  • Cooling molds in a fridge at a temperature of about 10 °C until a gel is formed (process block 1 - 5);
  • Freezing the gel in a freezer at a temperature of about -80 °C (process block 1 - 6); and Sublimating the solvent by drying the frozen gel at a temperature of about -45 °C and a pressure of about 0.313 torr to obtain a freeze-dried aerogel loaded by the pharmaceutically active material (process block 1 - 7).
  • the method may further include dissolving a sweetener and a flavoring agent in the solution.
  • the disintegration test for the pharmaceutical composition of the present disclosure was conducted for a sample released for 5 days at Room Temperature and Pressure (“RTP”) conditions.
  • the sample was tested through an in-house developed method, wherein the sample was of 5 ml in volume, tested in untreated water medium using a Petri dish, and the criterion of the test was having a complete disintegration within 30 seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present disclosure provides an oral pharmaceutical formulation that may include a pharmaceutically active material; a freeze-dried aerogel configured to be a polymeric carrier matrix of the pharmaceutically active material, wherein the freeze-dried aerogel may include a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material; an excipient configured to form and maintain a 3D structure of the carrier matrix; and a solvent configured to dissolve pharmaceutically active material in the freeze-dried aerogel.

Description

AN ORAL PHARMACEUTICAL FORMULATION AND A METHOD OF PREPARATION THEREOF
TECHNICAL FIELD
[001] The present disclosure relates to oral pharmaceutical formulations including carrier matrices for the oral delivery of a certain pharmaceutically active material, and more particularly to a pharmaceutical formulation that includes a polymeric carrier matrix of freeze-dried aerogel that rapidly disintegrates to release the pharmaceutically active material.
BACKGROUND
[002] The oral delivery system of pharmaceuticals administration is preferred because of being well-established delivery system, patient friendly, and used for treating several diseases. On the other hands, the oral delivery method suffers from challenges associated with poor oral bioavailability whether it is solubility, permeability, or stability-related. This could be overcome by the use of carrier matrices, self-emulsifying drug delivery systems, controlled release particles, tailor made nanoparticles, orally disintegrating tablets, or polymeric micelles.
[003] Many efforts have been dedicated for the sake of enhancing the bioavailability of oral drug delivery systems used for pharmaceuticals administration in the prior art. For instance, the publication titled “Gelatin based matrices for drug delivery applications” discloses the use of gelatin as a polymer carrier matrix in drug delivery system, wherein the Gelatin carriers can carry a variety of bioactive molecules while retaining their inherent biological activity. Furthermore, the Gelatin carriers have the ability to protect carried biomolecules from degradation and release them over extended periods of time.
[004] The published article titled “Gelatin content governs hydration induced structural changes in silica-gelatin hybrid aerogels - Implications in drug delivery” discloses silica- gelatin hybrid aerogels with varying gelatin content (4-24 wt.%) which can be impregnated with active agents (e.g. ibuprofen) and used as drug delivery systems. The active agents were amorphous, and homogeneously dispersed in the porous hybrid matrices as they were investigated by contrast variation neutron scattering experiments, those experiments showed the molecular level hybridization of the silica and the gelatin components of the aerogel carriers. The gelatin content of the carrier can govern the kinetics of drug release so that both fast and retarded drug release can be accomplished with using silica-gelatin aerogels as carrier matrices.
[005] The published article titled “Comparative Evaluation of HPMC, PVA and Gelatin as Matrices for Controlled Release Drug Delivery” discloses the use of gel-formers HPMC, PVA, and gelatin as polymeric matrices for formation of tablets, and compares the impact of each of the gel-formers on the drug release. The average drug release of drug formulated from different types of polymers varied with the ratio of different polymers. The PVA polymer showed best dissolution pattern between the polymers.
SUMMARY
[006] It is an object of the present disclosure to provide a pharmaceutical composition may include a freeze-dried aerogel configured to be a polymeric carrier matrix of a pharmaceutically active material, wherein the freeze-dried aerogel may include a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material intended to be orally delivered to a patient; an excipient configured to form and maintain a three-dimensional (“3D”) structure of the carrier matrix; and a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
[007] In some aspects of the present disclosure, the freeze-dried aerogel may further include a sweetener configured to sweeten the pharmaceutical composition.
[008] In some aspects, the sweetener may be D - Mannitol.
[009] In some aspects, the freeze-dried aerogel may further include a flavoring agent configured to facilitate an oral delivery of the pharmaceutically active material for pediatric patients.
[010] In some aspects, the flavoring agent may be cherry syrup.
[011] In yet some aspects, the plasticizer may be polyethylene glycol 400.
[012] In some aspects, the excipient may be gelatin.
[013] In some aspects, the solvent may be deionized water.
[014] In some aspects, the pharmaceutically active material may be paracetamol.
[015] In some aspects, the pharmaceutically active material may be acetylsalicylic acid.
[016] Other aspects of the present disclosure further provide a method of preparing the oral pharmaceutical formulation, the method may comprise the steps of: Dissolving an excipient, and a plasticizer in a solvent to form a solution;
Adding a pharmaceutically active material to the solution;
Mixing the solution while stirring until having a homogeneous solution;
Pouring the homogeneous solution into molds using a syringe;
Cooling molds until a gel is formed;
Freezing the gel; and
Sublimating the solvent by drying the frozen gel under pressure to obtain a freeze-dried aerogel loaded by the pharmaceutically active material.
[017] In some aspects, the method may further include dissolving a sweetener and a flavoring agent in the solution.
BRIEF DESCRIPTION OF THE DRAWINGS
[018] FIG.l illustrates a flow chart of a method of preparation of a pharmaceutical composition configured in accordance with embodiments of the present disclosure.
DETAILED DESCRIPTION
[019] Embodiments of the present disclosure provide an oral pharmaceutical formulation that may act as an oral delivery system for drugs, the formulation may include a pharmaceutically active material; a freeze-dried aerogel configured to be a polymeric carrier matrix of the pharmaceutically active material, wherein the freeze-dried aerogel may include a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material; an excipient configured to form and maintain a 3D structure of the carrier matrix; and a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
[020] In some embodiments of the present disclosure, the freeze-dried aerogel may further include a sweetener.
[021] In some embodiments, the sweetener may be D - Mannitol.
[022] In some embodiments, the freeze-dried aerogel may further include a flavoring agent configured to facilitate an oral delivery of the pharmaceutically active material for pediatric patients.
[023] In some embodiments, the flavoring agent may be cherry syrup. [024] In some embodiments, the plasticizer may be polyethylene glycol 400.
[025] In some embodiments, the excipient may be gelatin.
[026] In some embodiments, the solvent may be deionized water.
[027] In some embodiments, the pharmaceutically active material may be paracetamol.
[028] In some embodiments, the pharmaceutically active material may be acetylsalicylic acid.
[029] The disclosure is now further illustrated on the basis of examples and a detailed description from which further features and advantages may be taken. It is to be noted that the following explanations are presented for the sake of illustrating and description only; they are not intended to be exhaustive or to limit the disclosure to the precise form disclosed.
Example 1
Preparation of the pharmaceutical formulation
[030] In this example, reference is being made to FIG. 1, which illustrates a flowchart of a method for preparing the pharmaceutical formulation of the present disclosure. The pharmaceutical formulation was synthesized and tested for different pharmaceutically active materials, such pharmaceutically active materials validated the use of the freeze- dried aerogel as a carrier matrix for an orally delivered active pharmaceutical material. The pharmaceutically active materials were Paracetamol and Acetylsalicylic acid 400.
[031] The method of preparing the pharmaceutical formulation may include the steps of: Dissolving an excipient, and a plasticizer in a solvent to form a solution (process block 1 - i);
Adding a pharmaceutically active material to the solution (process block 1 - 2);
Mixing the solution at a temperature of about 75 °C while stirring at a rate of about 500 RPM until having a homogeneous solution (process block 1 - 3);
Pouring the homogeneous solution into molds using a syringe (process block 1 - 4);
Cooling molds in a fridge at a temperature of about 10 °C until a gel is formed (process block 1 - 5);
Freezing the gel in a freezer at a temperature of about -80 °C (process block 1 - 6); and Sublimating the solvent by drying the frozen gel at a temperature of about -45 °C and a pressure of about 0.313 torr to obtain a freeze-dried aerogel loaded by the pharmaceutically active material (process block 1 - 7).
[032] The method may further include dissolving a sweetener and a flavoring agent in the solution.
Example 2
Disintegration test of the pharmaceutical composition
[033] The disintegration test for the pharmaceutical composition of the present disclosure was conducted for a sample released for 5 days at Room Temperature and Pressure (“RTP”) conditions.
[034] The sample was tested through an in-house developed method, wherein the sample was of 5 ml in volume, tested in untreated water medium using a Petri dish, and the criterion of the test was having a complete disintegration within 30 seconds.
[035] The result of the disintegration test showed that the sample rapidly disintegrated, and the disintegration time was less than 30 seconds.

Claims

CLAIMS What is claimed is:
1. An oral pharmaceutical formulation as an oral drug delivery system, the formulation comprises a pharmaceutically active material; a freeze-dried aerogel configured to be a polymeric carrier matrix of the pharmaceutically active material, wherein the freeze-dried aerogel comprises a plasticizer configured to soften the freeze-dried aerogel carrying the pharmaceutically active material; an excipient configured to form and maintain a 3D structure of the carrier matrix; and a solvent configured to dissolve the pharmaceutically active material in the freeze-dried aerogel.
2. The oral pharmaceutical formulation of claim 1, wherein the freeze-dried aerogel further comprises a sweetener.
3. The oral pharmaceutical formulation of claim 2, wherein the sweetener is D - Mannitol.
4. The oral pharmaceutical formulation of claim 1, wherein the freeze-dried aerogel further comprises a flavoring agent configured to facilitate an oral delivery of the active pharmaceutical material for pediatric patients.
5. The oral pharmaceutical formulation of claim 4, wherein the flavoring agent is cherry syrup.
6. The oral pharmaceutical formulation of claim 1, wherein the plasticizer is polyethylene glycol 400.
7. The oral pharmaceutical formulation of claim 1 , wherein the excipient is gelatin.
8. The oral pharmaceutical formulation of claim 1, wherein the solvent is deionized water.
9. The oral pharmaceutical formulation of claim 1, wherein the pharmaceutically active material is paracetamol.
10. The oral pharmaceutical formulation of claim 1, wherein the pharmaceutically active material is acetylsalicylic acid.
11. A method of preparing the oral pharmaceutical formulation of claim 1, the method comprises the steps of:
Dissolving an excipient, and a plasticizer in a solvent to form a solution;
Adding an active pharmaceutical material to the solution;
Mixing the solution while stirring until having a homogeneous solution; Pouring the homogeneous solution into molds using a syringe;
Cooling molds until a gel is formed;
Freezing the gel; and
Sublimating the solvent by drying the frozen gel under pressure to obtain a freeze-dried aerogel loaded by the pharmaceutically active material.
12. The method of claim 11, further comprises dissolving a sweetener and a flavoring agent in the solution.
PCT/JO2023/050001 2023-01-10 2023-01-10 An oral pharmaceutical formulation and a method of preparation thereof Ceased WO2024150261A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JO2023/050001 WO2024150261A1 (en) 2023-01-10 2023-01-10 An oral pharmaceutical formulation and a method of preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JO2023/050001 WO2024150261A1 (en) 2023-01-10 2023-01-10 An oral pharmaceutical formulation and a method of preparation thereof

Publications (1)

Publication Number Publication Date
WO2024150261A1 true WO2024150261A1 (en) 2024-07-18

Family

ID=91896536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JO2023/050001 Ceased WO2024150261A1 (en) 2023-01-10 2023-01-10 An oral pharmaceutical formulation and a method of preparation thereof

Country Status (1)

Country Link
WO (1) WO2024150261A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372259B1 (en) * 1999-11-10 2002-04-16 University Of Iowa Research Foundation Palatable, sustained release drug granules
US6413549B2 (en) * 1997-07-11 2002-07-02 R. P. Scherer Corporation Fast-Dispersing solid oral dosage form containing coarse particles
US20040154317A1 (en) * 2003-02-07 2004-08-12 Ferro Corporation Lyophilization method and apparatus for producing particles
US20090062241A1 (en) * 2004-10-28 2009-03-05 Kurt Heinz Bauer Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step
US8362062B2 (en) * 2002-02-15 2013-01-29 Mcneil-Ppc, Inc. Pharmaceutical compositions with improved dissolution
US8821938B2 (en) * 1999-05-27 2014-09-02 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US9096335B2 (en) * 2010-03-29 2015-08-04 Ferring B.V. Fast dissolving pharmaceutical composition
US9125872B2 (en) * 2009-10-13 2015-09-08 Yosry A. Attia Polyethylene glycol aerogels for targeted delivery of pharmaceutical drubs
US20170088430A1 (en) * 2012-12-13 2017-03-30 Graduate School At Shenzhen, Tsinghua University Application of silicon dioxide aerogel as nano-drug carrying system in pharmacy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413549B2 (en) * 1997-07-11 2002-07-02 R. P. Scherer Corporation Fast-Dispersing solid oral dosage form containing coarse particles
US8821938B2 (en) * 1999-05-27 2014-09-02 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6372259B1 (en) * 1999-11-10 2002-04-16 University Of Iowa Research Foundation Palatable, sustained release drug granules
US8362062B2 (en) * 2002-02-15 2013-01-29 Mcneil-Ppc, Inc. Pharmaceutical compositions with improved dissolution
US20040154317A1 (en) * 2003-02-07 2004-08-12 Ferro Corporation Lyophilization method and apparatus for producing particles
US20090062241A1 (en) * 2004-10-28 2009-03-05 Kurt Heinz Bauer Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step
US9125872B2 (en) * 2009-10-13 2015-09-08 Yosry A. Attia Polyethylene glycol aerogels for targeted delivery of pharmaceutical drubs
US9096335B2 (en) * 2010-03-29 2015-08-04 Ferring B.V. Fast dissolving pharmaceutical composition
US20170088430A1 (en) * 2012-12-13 2017-03-30 Graduate School At Shenzhen, Tsinghua University Application of silicon dioxide aerogel as nano-drug carrying system in pharmacy

Similar Documents

Publication Publication Date Title
Zhou et al. Design and pharmaceutical applications of porous particles
Lee et al. Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal
KR101573510B1 (en) Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
EP2448567B1 (en) Drug delivery system comprising polyoxazoline and a bioactive agent
CN102686218B (en) Oral dosage form containing nanoparticle and the method that the formulation is prepared using fish glue
Yelles et al. PLGA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release
CN108136032A (en) Composite granulate comprising sugar or sugar alcohol, swelling binder, disintegrant and high-absorbency excipient and its production method
CN101193624B (en) Preparation of solid solutions based on poorly water-soluble active substances by short-term heating and rapid drying
JP2012504550A (en) Stabilization of amorphous drugs using a sponge-like carrier matrix.
CN102264351A (en) Preparation method of polymeric micelles composition containing poorly water-soluble drug
CN101961316B (en) A kind of LID-PEG-PLGA slow release nano microsphere and preparation method thereof
JP2011506395A (en) Salts of polymeric counter ions and active ingredients
CN102579362B (en) Felodipine slow-release microspheres and preparation method thereof
US9789065B2 (en) Process for producing oral dosage forms with controlled release
Akdag et al. Evaluation of preparation methods for orally disintegrating tablets
CN114159393B (en) Tetrandrine-loaded hybrid nanoparticles, tetrandrine-loaded soluble microneedle drug delivery system and preparation method thereof
Ofokansi et al. Formulation and evaluation of microspheres based on gelatin-mucin admixtures for the rectal delivery of cefuroxime sodium
WO2024240116A1 (en) Pharmaceutical sustained-release microsphere for injection and preparation method therefor
CN112870173A (en) Freeze-dried flash-release tablet and preparation method thereof
RU2600816C2 (en) Solid molecular dispersion
Ivone et al. Microbeads produced by prilling/vibration technique: A new way to use polyvinyl alcohol in pediatric and veterinary formulations
WO2024150261A1 (en) An oral pharmaceutical formulation and a method of preparation thereof
CN1295472A (en) carvedilol-galenical preparation
WO2004028534A1 (en) Controlled releases system containing temozolomide
Esuendale et al. Cellulosic on transdermal drug delivery system: a review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23915885

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23915885

Country of ref document: EP

Kind code of ref document: A1